Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

Rhea-AI Summary

Mustang Bio, Inc. (NASDAQ: MBIO) announced its management team's participation in three virtual investor conferences in March 2021. The events include:

• H.C. Wainwright Global Life Sciences Virtual Conference on March 9, 2021, available on-demand.
• Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, with a fireside chat at 3:10 p.m. ET.
• Redburn Virtual Gene Therapy Summit on March 31, 2021, at 9:15 a.m. ET.

Webcasts will be accessible on Mustang's website for 30 days following each event.

WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Mustang’s management team will participate in three virtual investor conferences in March 2021.

Details of the events are as follows:

• H.C. Wainwright Global Life Sciences Virtual Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET.
• Oppenheimer 31^st Annual Virtual Healthcare Conference: The company’s fireside chat will take place on Tuesday, March 16, 2021, at 3:10 p.m. ET.
• Redburn Virtual Gene Therapy Summit: The company’s management team will participate in a panel that will take place on Wednesday, March 31, 2021, at 9:15 a.m. ET.
  

Webcasts of the H.C. Wainwright presentation and Oppenheimer fireside chat will be available on the Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days.

About Mustang Bio
Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:
Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

What investor conferences will Mustang Bio participate in March 2021?

Mustang Bio will participate in three virtual conferences: H.C. Wainwright on March 9, Oppenheimer on March 16, and Redburn on March 31.

What is the schedule for Mustang Bio's presentations at these conferences?

Mustang's presentation for H.C. Wainwright is on-demand from March 9, the Oppenheimer chat is on March 16 at 3:10 p.m. ET, and the Redburn panel is on March 31 at 9:15 a.m. ET.

How can I access Mustang Bio's webcasts from the conferences?

Webcasts will be available on Mustang Bio's website for approximately 30 days after each event.

What is Mustang Bio focused on in their business strategy?

Mustang Bio focuses on cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.

Where can I find more information about Mustang Bio's investor relations?

More information about Mustang Bio's investor relations can be found on their official website at www.mustangbio.com.